NCT00942682View on ClinicalTrials.gov

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Neuroendocrine TumorCarcinoid TumorPancreatic Neuroendocrine Tumor
Interventions
DRUG

Sorafenib

Taken orally twice daily

DRUG

RAD001

Taken orally once daily in the morning

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Novartis
Bayer
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00942682 - Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter